RemeGen
Manufacturing · China · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Economic and Technological Development Z...Phone Number
+86 118783Website
www.remegen.comRevenue
$147.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About RemeGen
RemeGen is a biopharmaceutical company focused on developing innovative drugs for autoimmune diseases and cancers. Their flagship products include Telitacicept, a dual-target fusion protein for autoimmune conditions, and Disitamab Vedotin, an antibody-drug conjugate for cancer treatment. The company has a robust product pipeline with numerous drugs in various stages of research and development. RemeGen aims to serve patients globally, leveraging its advanced technology and strong scientific support.Explore more
RemeGen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RemeGen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if RemeGen is spiking on competitors!
RemeGen, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if RemeGen has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once RemeGen has new funding data
Click to see if RemeGen had a recent Job posting/layoffs
Earning: See what the market has to say on RemeGen recently announced quarterly report
Product Launch: Get notified when RemeGen launches new products
Congratulate Masked Content for being promoted to Masked Content at RemeGen
Recommended Actions
Reach out to Masked Content who joined RemeGen as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
RemeGen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
RemeGen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about RemeGen.
RemeGen Tech Stack
A closer look at the technologies used by RemeGen
See more technologies
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
RemeGen News & Media
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations
AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancers NORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the...RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned...RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of multiple advanced malignant solid tumors in the US. RC148 is a PD-1 and VEGF-targeting bispecific antibody, an innovative molecule developed by RemeGen using its bispecific antibody technology platform. Currently, t
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RemeGen
Sign Up For FreeTo access detailed company insights
RemeGen is a biopharmaceutical company focused on developing innovative drugs for autoimmune diseases and cancers. Their flagship products include Telitacicept, a dual-target fusion protein for autoimmune conditions, and Disitamab Vedotin, an antibody-drug conjugate for cancer treatment. The company has a robust product pipeline with numerous drugs... Read More
